Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals Ltd. focused on oncology, immunology, and critical care, has announced the U.S. commercial launch of IMULDOSA® (ustekinumab-srlf), a biosimilar to STELARA® (ustekinumab).
IMULDOSA prefilled syringes, which make up the majority of ustekinumab use, are priced at the lowest wholesaler acquisition cost (WAC) among branded ustekinumab biosimilars—a 92% discount compared to STELARA®. The vial formulation is also available at a 33% discount. FDA-approved for all the same indications as the reference product, IMULDOSA is Accord BioPharma’s third in-market biosimilar, strengthening its commitment to expanding access to high-value biologics.
Immune-mediated inflammatory conditions—including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis—impact millions of Americans, causing chronic pain and reduced quality of life. While STELARA® has transformed treatment, its high cost limits accessibility. IMULDOSA offers a clinically equivalent, more affordable option, with no clinically meaningful differences from STELARA®.
To further support patients, Accord BioPharma is introducing a $0 co-pay program for eligible patients, making biologic therapy more accessible.
Chrys Kokino, U.S. President of Accord BioPharma, stated: “At Accord, cost should never be a barrier to proven therapies. IMULDOSA is more than a biosimilar—it’s part of a comprehensive approach to expand care and reduce burden for patients.”
Backed by the 50-year legacy of Intas Pharmaceuticals, Accord BioPharma continues to drive biosimilar innovation in the U.S. market.